Hemp Research — Page 141

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

Case report: Alexander's disease with “head drop” as the main symptom and literature review (2022)

Alexander's disease (AxD) is a rare autosomal dominant hereditary disorder that is caused by the mutations in the GFAP gene, which encodes the glial fibrillary acidic protein (GFAP). This neurogenerative disease has many clinical manifestations, and the onset of disease spans a wide range of ages, from newborns to children, adults, and even the elderly. An overaccumulation of the expression of GFAP has a close causal relationship with the pathogenesis of Alexander's disease. Usually, the disease

Quinine in the Treatment of Malignant Migrating Partial Seizures in Infancy: A Case Report (2021)

The syndrome of malignant migrating partial seizures in infancy was first described by Coppola and colleagues in 1995. The International League Against Epilepsy defines this form of epilepsy as a seizure onset in the first 6 months of life, occurrence of almost continuous migrating polymorphous focal seizures, combined with multifocal ictal EEG discharges, and progressive deterioration of psychomotor development. Most cases are pharmacoresistant and have poor outcomes. A lot of publications desc

Delineating clinical and developmental outcomes in STXBP1 -related disorders (2023)

<i>STXBP1</i>-related disorders are among the most common genetic epilepsies and neurodevelopmental disorders. However, the longitudinal epilepsy course and developmental endpoints have not yet been described in detail, which is a critical prerequisite for clinical trial readiness. Here, we assessed 1,281 cumulative patient-years of seizure and developmental histories in 162 individuals with <i>STXBP1</i>-related disorders and established a natural history framework. <i>STXBP1</i>-related disord

The SCN1A Philadelphia variant – a gain-of-function mutation causing an early-onset epileptic encephalopathy (2022)

Abstract Objective Loss-of-function variants in SCN1A cause Dravet Syndrome, the most common genetic developmental and epileptic encephalopathy (DEE). However, emerging evidence suggests separate entities of SCN1A -related disorders due to gain-of-function variants. Here, we aim to refine the clinical, genetic, and functional electrophysiological features of a recurrent p.R1636Q gain-of-function variant, identified in four individuals at a single center. Methods Individuals carrying the recurren

A formação compartilhada do futuro professor que ensinará matemática: contrapontos à BNC-formação (2022)

O presente texto centra-se na análise de uma parceria estabelecida entre a formadora do curso de Pedagogia e sua orientanda, professora dos anos iniciais do Ensino Fundamental, que possibilitou uma formação compartilhada para as práticas de ensino de Matemática. Tem como objetivo apontar indícios de como essa parceria possibilitou aprendizagens aos futuros professores. A análise, centrada nas narrativas produzidas pelos graduandos ao final do curso, pautou-se em três unidades temáticas que emerg

Clinical signatures of SYNGAP1- related disorders through data integration (2024)

ABSTRACT Objective To characterize the longitudinal disease and treatment histories of individuals with SYNGAP1- related disorders. Methods Participants with SYNGAP1 were identified from a range data data sources, including insurance claims data by ICD-10 diagnosis codes ( n =246), a specialized medical record registry and a local cohort followed at a single tertiatry health care institution ( n =158). Results Compared to a broader population of individuals with epilepsy, phenotypes associated w

Observation On The Efficacy Of Xiao Chai Hu Tang Plus Minus Tang Combined With Sodium Valproate In The Treatment Of Meningitis-Associated Epilepsy (2025)

Meningitis is a neurological condition that can be severe causing epilepsy. This study analyzed the efficacy of Xiao Chai Hu Tang plus minus Tang combined with sodium valproate in the treatment of meningitis-associated epilepsy. 100 patients with meningitis-associated epilepsy during June 2022 to June 2024 were randomised to control group (n=50) and study group (n=50). Both groups were treated with sodium valproate and study group was added Xiao Chai Hu Tang plus minus Tang treatment. To evaluat

Research on the treatment of Rett syndrome (2024)

Rett syndrome (RS) is a genetically determined nerodevelopmental disorder that mainly affects females. The most common cause is a mutation in the MECP2 gene on the long arm of the X chromosome. In the phenotype of the syndrome, dominant symptoms from the nervous system are observed, such as speech and motor regression, stereotypical hand movements, intellectual disability, seizures and breathing disorders. Clinical manifestation also includes the skeletal system (short stature, scoliosis, osteop

Potential Drug Interactions with Cannabinoids in Selected Chronic Diseases: Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis and Pain (2024)

The clinical practice implies a research translation that helps the use of scientific data and thera-peutic evidence for patient benefits. This review critically summarizes the potential impact of cannabinoids in concomitance with other drugs in the following chronic diseases as Epilepsy, Au-tism Spectrum Disorders (ASD), Oncology, Multiple Sclerosis, and Chronic Pain. The potential in-teractions can change the predicted clinical outcomes of therapeutic protocols and need to be evaluated. Some o

Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease (2025)

Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treatments to stop neurodegeneration or promote neuronal regeneration in AD remain elusive. Psychoactive substances as modulators of neurophysiological functions, have received increased attention in research. The main psychoactive agents, such as central nervous system depressants and stimulants, cannab

Folate transfer in placental choriocarcinoma cells treated with valproic acid: Insights gained through comparisons with the amide derivative sec‐butylpropylacetamide and its individual stereoisomers (2025)

Altered expression of the studied carriers could not explain the folate transfer kinetics across placental cell monolayers. Future studies should assess the effects of VPA and other antiseizure medications on transplacental transfer of essential compounds in vivo and the ability to predict it by functional in vitro assays.

Identification of genetic variants in a pedigree associated with epilepsy by using whole exome sequencing and whole genome sequencing (2021)

Epilepsy is a common heterogeneous group of neurological disorders including electroencephalographic and brain imaging. We used whole exome sequencing and whole genome sequencing to identify variants in a pedigree associated with epilepsy. Cranium CT scan showed that the lateral right parietal lobe was hyperdense, and there were no clear boundaries with brain tissue in affected cases. Using WES, one exclusive nonsynonymous mutant in gene TSC2 (Chr16:2138307; c.5240 T &gt; G; p.Ile1747Ser) was in

National Institute for Health and Care Excellence (NICE) Guidelines on Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management (2020)

The UK’s National Institute for Health and Care Excellence (NICE) has produced new evidence-based guidance on the prescription of cannabis-based medicinal products (CBMP) to treat epilepsy, chronic pain, spasticity, and intractable nausea and vomiting. For epilepsy, cannabidiol (CBD) (Epidyolex®, GW Pharmaceuticals, Cambridge, UK) is recommended in conjunction with clobazam for treating seizures associated with Lennox–Gastaut syndrome and Dravet syndrome in patients aged ≥2 years. Other CBMP cov

The current state of pharmacotherapy for extrapyramidal diseases (2021)

Farmakoterapie extrapyramidových onemocnění zažívala svůj boom v průběhu devadesátých let minulého století, spíše v jeho druhé polovině, kdy většina klinických hodnocení v neurologických indikacích zkoumala efekt různých molekul na Parkinsonovu nemoc (PN) a další extrapyramidová onemocnění. Další dekáda byla v této oblasti ve znamení pozvolného útlumu velkých klinických hodnocení a na významu nabývalo zavádění nákladných forem léčby pokročilého s

Taking a Newer, Faster, Intranasal Route: A Narrative Review of Transitioning to a Less-Invasive Rescue Treatment for Seizure Clusters (2024)

In the US, 3 rescue treatment options are approved for patients with seizure clusters (ie, acute repetitive seizures), which are intermittent increases of seizure activity. This narrative PubMed review of these 3 treatments examines newer intranasal options that are well suited for adolescent and adult patients who may desire a transition from rectal treatment. Diazepam rectal gel is indicated for patients ≥2 years, diazepam nasal spray for those ≥6 years, and midazolam nasal spray for those ≥12

Environmental modifiers of developmental outcomes in genetic epilepsy (2025)

Abstract Genetic neurodevelopmental disorders (NDDs) with epilepsy are genome-defined yet exposure-sensitive. While the mechanistic effects of genetic variants underlying these disorders are widely studied to understand clinical heterogeneity among patients, the contribution of external environmental factors remains largely unexplored. Using the Simons Searchlight population dataset, we examined caregiver-reported environmental exposures and functional outcomes from 970 individuals with (67%) an

Unusual Guillain-Barre syndrome with normal myotatic reflexes (2024)

Case Presentation: AGRB, male, 9 years old, 52kg, previously healthy, born and raised in Pirambu, Bebedouro village, Sergipe.Adtted on 10/09/2022 to the pediatrics sector of the Sergipe Emergency hospital, reporting headache, fever and vomiting for 7 days, with subsequent evolution with pain in the posterior region of the right thigh, in addition to low back pain.Physical examination showed normal breathing and heart rate.Decreased strength in lower limbs, being worse on the left side.No patella